Autogene cevumeran
- Generic Name
- Autogene cevumeran
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2365453-34-3
- Unique Ingredient Identifier
- L8HDH9IB06
- Background
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 362
- Registration Number
- NCT06534983
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇩🇪Uniklinikum Heidelberg, Heidelberg, Germany
🇮🇹IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, Italy
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05968326
- Locations
- 🇪🇸
Centro Integral Oncológico Clara Campal Ensayos ClÃnicos START, Madrid, Spain
🇬🇧Addenbrookes Hospital; Cambridge Cancer Trials Centre, S4 Box 279, Cambridge, United Kingdom
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
- Conditions
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT03815058
- Locations
- 🇺🇸
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California San Diego Moores Cancer Center, La Jolla, California, United States
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03289962
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Can Ins, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.